Related Experiment Videos
Tyrosine kinase src inhibitors: potential therapeutic applications
1Department of Arthritis and Bone Metabolism, Unit Bone Metabolism, Research Bone Metabolism, Novartis Pharma AG, Basel, Switzerland.
Drug News & Perspectives
|August 26, 2003
Summary
Tyrosine kinase Src plays a key role in bone resorption. New Src family kinase inhibitors show therapeutic potential for bone loss and bone metastases, offering a novel treatment strategy.
Area of Science:
- Biochemistry
- Oncology
- Bone Biology
Background:
- The tyrosine kinase Src is a proto-oncogene and a prototype for non-receptor tyrosine kinases.
- Src has a critical role in osteoclast function and bone resorption.
- Research into Src's specific substrates and functions is ongoing.
Purpose of the Study:
- To review the cellular and molecular mechanisms of Src kinase inhibitors.
- To explore the therapeutic potential of Src kinase inhibitors in bone diseases and cancer-induced bone metastases.
Main Methods:
- Review of recent scientific literature on Src kinase inhibitors.
- Analysis of cellular and animal models of bone loss.
- Characterization of selective, potent, and orally available Src family kinase inhibitors.
Main Results:
- Src family kinase inhibitors have been identified and characterized.
- These inhibitors demonstrate potential in preclinical models of bone loss.
- The mechanisms through which these inhibitors act are being elucidated.
Conclusions:
- Src kinase inhibitors represent a novel therapeutic tool.
- They hold promise for treating bone disorders and bone metastases from cancer.
- Further research into their application is warranted.